Digoxin Induces Human Astrocyte Reaction In Vitro.


Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 22 06 2022
accepted: 21 09 2022
pubmed: 13 10 2022
medline: 21 12 2022
entrez: 12 10 2022
Statut: ppublish

Résumé

Astrocyte reaction is a complex cellular process involving astrocytes in response to various types of CNS injury and a marker of neurotoxicity. It has been abundantly studied in rodents but relatively poorly in human cells due to limited access to the brain. Astrocytes play important roles in cerebral energy metabolism and are also key players in neuroinflammation. Astroglial metabolic and inflammatory changes have been reported with age, leading to the hypothesis that mitochondrial metabolism and inflammatory responses are interconnected. However, the relationship between energy metabolism and astrocyte reactivity in the context of neurotoxicity is not known. We hypothesized that changes in energy metabolism of astrocytes will be coupled to their activation by xenobiotics. Astrocyte reaction and associated energy metabolic changes were assessed by immunostaining, gene expression, proteomics, metabolomics, and extracellular flux analyses after 24 h of exposure of human ReN-derived astrocytes to digoxin (1-10 µM) or TNFα (30 ng/ml) used as a positive control. Strong astrocytic reaction was observed, accompanied by increased glycolysis at low concentrations of digoxin (0.1 and 0.5 µM) and after TNFα exposure, suggesting that increased glycolysis may be a common feature of reactive astrocytes, independent of the triggering molecule. In conclusion, whether astrocyte activation is triggered by cytokines or a xenobiotic, it is strongly tied to energy metabolism in human ReN-derived astrocytes. Increased glycolysis might be considered as an endpoint to detect astrocyte activation by potentially neurotoxic compounds in vitro. Finally, ReN-derived astrocytes may help to decipher mechanisms of neurotoxicity in ascertaining the ability of chemicals to directly target astrocytes.

Identifiants

pubmed: 36223047
doi: 10.1007/s12035-022-03057-1
pii: 10.1007/s12035-022-03057-1
pmc: PMC9758102
doi:

Substances chimiques

Digoxin 73K4184T59
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

84-97

Subventions

Organisme : Swiss Center for Applied Human Toxicology (SCAHT)
ID : CP3

Informations de copyright

© 2022. The Author(s).

Références

Cancers (Basel). 2019 Aug 26;11(9):
pubmed: 31454998
J Pharmacol Exp Ther. 1965 Mar;147:409-15
pubmed: 14269618
Neuroscience. 2019 Dec 15;423:38-54
pubmed: 31682945
Neurotoxicology. 1995 Spring;16(1):97-104
pubmed: 7603649
Anal Chim Acta. 2020 Apr 8;1105:28-44
pubmed: 32138924
Adv Exp Med Biol. 2017;975 Pt 1:89-94
pubmed: 28849446
Lancet. 1973 Dec 22;2(7843):1453-4
pubmed: 4128774
J Biol Chem. 2011 Sep 16;286(37):32002-10
pubmed: 21778230
J Biol Chem. 1988 Oct 25;263(30):15335-41
pubmed: 3170585
N Engl J Med. 1997 Feb 20;336(8):525-33
pubmed: 9036306
Aging Cell. 2014 Dec;13(6):1059-67
pubmed: 25233945
Cell Metab. 2020 Oct 6;32(4):524-536
pubmed: 32853548
J Proteomics. 2015 Nov 3;129:108-120
pubmed: 26381204
Brain Struct Funct. 2017 Jul;222(5):2017-2029
pubmed: 28280934
Acta Neuropathol. 2010 Jan;119(1):7-35
pubmed: 20012068
Int J Mol Sci. 2021 Jul 25;22(15):
pubmed: 34360699
Br J Pharmacol. 1977 Feb;59(2):223-9
pubmed: 13903
Prog Neurobiol. 2000 Dec;62(6):649-71
pubmed: 10880854
Biomed Environ Sci. 1991 Jun;4(1-2):197-206
pubmed: 1910596
Toxicol Appl Pharmacol. 2004 Dec 1;201(2):97-104
pubmed: 15541749
Crit Pathw Cardiol. 2011 Jun;10(2):93-8
pubmed: 21988950
Cell Host Microbe. 2013 Jan 16;13(1):87-99
pubmed: 23332158
J Chromatogr A. 2019 May 10;1592:47-54
pubmed: 30685186
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86
pubmed: 19020076
Neurotoxicol Teratol. 2010 Jan-Feb;32(1):36-41
pubmed: 19150401
J Neurochem. 2006 Aug;98(3):641-53
pubmed: 16787421
Am J Psychiatry. 1987 Apr;144(4):506-7
pubmed: 3565623
Sci Rep. 2019 Sep 25;9(1):13899
pubmed: 31554907
Chem Cent J. 2013 Feb 25;7(1):38
pubmed: 23442334
Int J Mol Sci. 2021 Apr 14;22(8):
pubmed: 33920048
Biochemistry. 2005 Jul 12;44(27):9417-29
pubmed: 15996096
Braz J Med Biol Res. 1999 May;32(5):619-31
pubmed: 10412574
J Neuroinflammation. 2018 Nov 30;15(1):331
pubmed: 30501627
Neuroscience. 2005;134(3):771-82
pubmed: 15994020
Am J Respir Cell Mol Biol. 1999 Dec;21(6):710-8
pubmed: 10572068
Methods Mol Biol. 2017;1613:101-124
pubmed: 28849560
Trends Immunol. 2016 Sep;37(9):608-620
pubmed: 27443914
Mol Neurobiol. 2021 Apr;58(4):1792-1805
pubmed: 33394334
J Neural Transm (Vienna). 2006 Nov;113(11):1709-15
pubmed: 16736247
Neurochem Res. 2015 Dec;40(12):2570-82
pubmed: 25428182
J Neurosci Res. 2002 Oct 1;70(1):108-16
pubmed: 12237869
J Exp Biol. 2006 Jun;209(Pt 12):2304-11
pubmed: 16731806
J Neurosci Res. 2014 Jan;92(1):95-103
pubmed: 24123177
Toxicol Lett. 2014 Oct 15;230(2):188-97
pubmed: 24521700
Chem Biol Interact. 2022 Jan 5;351:109740
pubmed: 34742682
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cold Spring Harb Perspect Biol. 2014 Nov 07;7(2):a020420
pubmed: 25380660
Expert Opin Drug Saf. 2005 May;4(3):433-42
pubmed: 15934851
Glia. 2019 Dec;67(12):2221-2247
pubmed: 31429127
Redox Biol. 2019 Jun;24:101223
pubmed: 31141786
Arch Toxicol. 2019 Jun;93(6):1649-1664
pubmed: 30993381
J Card Fail. 2017 Aug;23(8):628-651
pubmed: 28461259
Br Med J (Clin Res Ed). 1982 Jan 16;284(6310):162-3
pubmed: 6799080
Toxicol In Vitro. 2013 Jun;27(4):1416-24
pubmed: 22954530
Am J Ther. 2011 Sep;18(5):366-70
pubmed: 20093923
J Chem Neuroanat. 2008 May;35(3):285-94
pubmed: 18358697

Auteurs

David Pamies (D)

Department of Biological Sciences, University of Lausanne, Lausanne, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Tatjana Vujić (T)

Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Domitille Schvartz (D)

Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Julien Boccard (J)

Translational Biomarker Group, Department of Medicine, University of Geneva, Geneva, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Cendrine Repond (C)

Department of Biological Sciences, University of Lausanne, Lausanne, Switzerland.

Carolina Nunes (C)

Department of Biological Sciences, University of Lausanne, Lausanne, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Serge Rudaz (S)

Translational Biomarker Group, Department of Medicine, University of Geneva, Geneva, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Jean-Charles Sanchez (JC)

Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Víctor González-Ruiz (V)

Translational Biomarker Group, Department of Medicine, University of Geneva, Geneva, Switzerland.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Marie-Gabrielle Zurich (MG)

Department of Biological Sciences, University of Lausanne, Lausanne, Switzerland. mzurich@unil.ch.
School of Pharmaceutical Sciences and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland. mzurich@unil.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH